Some antiseizure drugs used to treat epilepsy as well as depression, chronic pain, migraine, bipolar disorder, and other conditions are said to be associated with a higher risk of suicide and violent death than other drugs in the same class, according to a new study. Experts caution that patients should not stop taking the drugs — gabapentin (Neurontin), lamotrigine (Lamictal), oxcarbazepine (Trileptal), tiagabine (Gabitril), and valproate (Depakote) — without their doctor’s permission. It’s still not clear whether these risks are related to the drugs themselves or to underlying mood problems.
The study, published last month in the Journal of the American Medical Association, echoes a 2008 review by the U.S. Food and Drug Administration that found that taking anticonvulsants (as this class of drugs is known) roughly doubled the risk of suicidal thoughts and suicide attempts, although the absolute risk remained small — less than one-half of one percent.
According to the FDA analysis, which included 11 anticonvulsants, the risk that a person taking those drugs would exhibit suicidal behavior or have suicidal thoughts was about one in 230, compared to about one in 450 in people taking a placebo. As a result, the FDA required that the label of all anticonvulsants carry a warning about this increased risk. It should be noted that the agency stopped short of requiring a black box warning similar to those found on the labels of other antidepressant drugs.
The use of anticonvulsants has risen in recent years, among adults as well as children and teens. It’s being reported that doctors are increasingly prescribing the drugs off-label, meaning the drugs are not officially approved by the FDA for that condition. In the new study, a team of researchers led by Elisabetta Patorno, MD, a research fellow at Brigham and Women’s Hospital in Boston, looked at prescription data for 13 different anticonvulsants from health plans across the country and compared them to federal death records and data on emergency room visits and hospitalizations.
Contact us today for a free legal consultation with an experienced attorney.
Fields marked *may be required for submission.
If you would like to subscribe to the Jere Beasley Report digital edition, simply visit our Subscriptions page and provide the necessary information or call us at 800-898-2034.
Attorney Advertising - Prior results do not guarantee a similar outcome.